Pasar al contenido principal

EVALUACION DE LA PREVENCION DEL CANCER DE MAMA MEDIANTE ANALOGOS DE LA SOMATOSTATINA

PID2020-118527RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Pathophysiological integration of metabolic reprogramming in breast cancer

  • Corchado Cobos, Roberto
  • García-Sancha, Natalia
  • Mendiburu-Eliçabe, Marina
  • Gómez-Vecino, Aurora
  • Jiménez-Navas, Alejandro
  • Pérez-Baena, Manuel Jesús
  • Holgado-Madruga, Marina
  • Mao, Jian-Hua
  • Cañueto, Javier
Metabolic changes that facilitate tumor growth are one of the hallmarks of cancer. The triggers of these metabolic changes are located in the tumor parenchymal cells, where oncogenic mutations induce an imperative need to proliferate and cause tumor initiation and progression. Cancer cells undergo significant metabolic reorganization during disease progression that is tailored to their energy demands and fluctuating environmental conditions. Oxidative stress plays an essential role as a trigger under such conditions. These metabolic changes are the consequence of the interaction between tumor cells and stromal myofibroblasts. The metabolic changes in tumor cells include protein anabolism and the synthesis of cell membranes and nucleic acids, which all facilitate cell proliferation. They are linked to catabolism and autophagy in stromal myofibroblasts, causing the release of nutrients for the cells of the tumor parenchyma. Metabolic changes lead to an interstitium deficient in nutrients, such as glucose and amino acids, and acidification by lactic acid. Together with hypoxia, they produce functional changes in other cells of the tumor stroma, such as many immune subpopulations and endothelial cells, which lead to tumor growth. Thus, immune cells favor tissue growth through changes in immunosuppression. This review considers some of the metabolic changes described in breast cancer., J.P.-L.’s laboratory was partially supported by Grant SAF2017-88854R funded by MCIN/AEI/10.13039/501100011039 and by “ERDF A way of making Europe”; Grant PID2020- 118527RB-I00 funded by MCIN/AEI/10.13039/501100011039; Grant PDC2021-121735-I00 funded by MCIN/AEI/10.13039/501100011039 and by the “European Union Next Generation EU/PRTR”. The Carlos III Health Institute (PIE14/00066), the Regional Government of Castile and León (CSI234P18 and CSI144P20) and the “We can be heroes” charity. SCLl was the recipient of a Ramón y Cajal research contract from the Spanish Ministry of Economy and Competitiveness and was supported by grant RTI2018-094130-B-100 funded by MCIN/AEI/10.13039/501100011039 and by “ERDF A way of making Europe”. R.C.-C. and A.J.-N. are funded by fellowships from the Spanish Regional Government of Castile and León. N.G.-S. is a recipient of an FPU fellowship (MINECO/FEDER). M.J.P.-B. is funded by grant PID2020-118527RB-I00 funded by MCIN/AEI/10.13039/501100011039. J.C. is partially supported by grant GRS2139/A/20 (Gerencia Regional de Salud de Castilla y León) and by the Instituto de Salud Carlos III (PI18/00587 and PI21/01207), co-financed by FEDER funds, and by the “Programa de Intensificación” of the ISCIII, grant number INT20/00074.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Evolutionary origins of metabolic reprogramming in cancer

  • García-Sancha, Natalia
  • Corchado Cobos, Roberto
  • Gómez-Vecino, Aurora
  • Jiménez-Navas, Alejandro
  • Pérez-Baena, Manuel Jesús
  • Blanco-Gómez, Adrián
  • Holgado-Madruga, Marina
  • Mao, Jian-Hua
  • Cañueto, Javier
  • Castillo-Lluva, Sonia
  • Mendiburu-Eliçabe, Marina
  • Pérez-Losada, J.
Metabolic changes that facilitate tumor growth are one of the hallmarks of cancer. These changes are not specific to tumors but also take place during the physiological growth of tissues. Indeed, the cellular and tissue mechanisms present in the tumor have their physiological counterpart in the repair of tissue lesions and wound healing. These molecular mechanisms have been acquired during metazoan evolution, first to eliminate the infection of the tissue injury, then to enter an effective regenerative phase. Cancer itself could be considered a phenomenon of antagonistic pleiotropy of the genes involved in effective tissue repair. Cancer and tissue repair are complex traits that share many intermediate phenotypes at the molecular, cellular, and tissue levels, and all of these are integrated within a Systems Biology structure. Complex traits are influenced by a multitude of common genes, each with a weak effect. This polygenic component of complex traits is mainly unknown and so makes up part of the missing heritability. Here, we try to integrate these different perspectives from the point of view of the metabolic changes observed in cancer., This work was supported in JPL’s lab by Grant PID2020-118527RB-I00 funded by MCIN/AEI/10.13039/501100011039; Grant PDC2021-121735-I00 funded by MCIN/AEI/10.13039/501100011039 and by the “European Union Next Generation EU/PRTR.”, the Regional Government of Castile and León (CSI234P18 and CSI144P20). SCLl was the recipient of a Ramón y Cajal research contract from the Spanish Ministry of Economy and Competitiveness and was supported by grant RTI2018-094130-B-100 funded by MCIN/AEI/10.13039/501100011039 and by “ERDF A way of making Europe.” RCC and AJN are funded by fellowships from the Spanish Regional Government of Castile and León. NGS is a recipient of an FPU fellowship (MINECO/FEDER). MJPB is funded by grant PID2020-118527RB-I00 funded by MCIN/AEI/10.13039/501100011039. J.C. is partially supported by grant GRS2139/A/20 (Gerencia Regional de Salud de Castilla y León) and by the Instituto de Salud Carlos III (PI18/00587 and PI21/01207), co-financed by FEDER funds, and by the “Programa de Intensificación” of the ISCIII, grant number INT20/00074. We thank Phil Mason for English language support.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Intermediate Molecular Phenotypes to Identify Genetic Markers of Anthracycline-Induced Cardiotoxicity Risk

  • Gómez-Vecino, Aurora
  • Corchado Cobos, Roberto
  • Blanco-Gómez, Adrián
  • García-Sancha, Natalia
  • Castillo-Lluva, Sonia
  • Martin-Garcia, Ana
  • Mendiburu-Eliçabe, Marina
  • Prieto, Carlos
  • Ruiz-Pinto, Sara
  • Pita, Guillermo
  • Velasco-Ruiz, Alejandro
  • Patino-Alonso, María Carmen
  • Galindo-Villardón, Purificación
  • Linarejos Vera-Pedrosa, María
  • Jalife, José
  • Mao, Jian-Hua
  • Macías de Plasencia, Guillermo
  • Castellanos-Martín, Andrés
  • Sáez-Freire, María Del Mar
  • Fraile, Susana
  • Rodrigues Teixeira, Telmo
  • García-Macías, Carmen
  • Galvis-Jiménez, Julie Milena
  • García Sánchez, Asunción
  • Isidoro-García, María
  • Fuentes, Manuel
  • García-Cenador, Begoña
  • García-Criado, Francisco Javier
  • García, Juan L.
  • Hernández-García, María Ángeles
  • Cruz, Juan Jesús
  • Rodríguez-Sánchez, César Augusto
  • García-Sancho, Alejandro Martín
  • Pérez-López, Estefanía
  • Pérez-Martínez, Antonio
  • Gutiérrez-Larraya, Federico
  • Cartón, Antonio J
  • García-Sáenz, José Ángel
  • Patiño-García, Ana
  • Martín, Miguel
  • Alonso Gordoa, Teresa
  • Vulsteke, Christof
  • Croes, Lieselot
  • Hatse, Sigrid
  • Van Brussel, Thomas
  • Lambrechts, Diether
  • Wildiers, Hans
  • Chang, Hang
  • Holgado-Madruga, Marina
  • González-Neira, Anna
  • Sánchez, Pedro L.
  • Pérez-Losada, J.
This article belongs to the Collection Cardiovascular Disease: From Molecular and Cellular Mechanisms to Therapeutic Opportunities., Cardiotoxicity due to anthracyclines (CDA) affects cancer patients, but we cannot predict who may suffer from this complication. CDA is a complex trait with a polygenic component that is mainly unidentified. We propose that levels of intermediate molecular phenotypes (IMPs) in the myocardium associated with histopathological damage could explain CDA susceptibility, so variants of genes encoding these IMPs could identify patients susceptible to this complication. Thus, a genetically heterogeneous cohort of mice (n = 165) generated by backcrossing were treated with doxorubicin and docetaxel. We quantified heart fibrosis using an Ariol slide scanner and intramyocardial levels of IMPs using multiplex bead arrays and QPCR. We identified quantitative trait loci linked to IMPs (ipQTLs) and cdaQTLs via linkage analysis. In three cancer patient cohorts, CDA was quantified using echocardiography or Cardiac Magnetic Resonance. CDA behaves as a complex trait in the mouse cohort. IMP levels in the myocardium were associated with CDA. ipQTLs integrated into genetic models with cdaQTLs account for more CDA phenotypic variation than that explained by cda-QTLs alone. Allelic forms of genes encoding IMPs associated with CDA in mice, including AKT1, MAPK14, MAPK8, STAT3, CAS3, and TP53, are genetic determinants of CDA in patients. Two genetic risk scores for pediatric patients (n = 71) and women with breast cancer (n = 420) were generated using machine-learning Least Absolute Shrinkage and Selection Operator (LASSO) regression. Thus, IMPs associated with heart damage identify genetic markers of CDA risk, thereby allowing more personalized patient management., J.P.L.’s lab is sponsored by Grant PID2020-118527RB-I00 funded by MCIN/AEI/10.13039/501100011039; Grant PDC2021-121735-I00 funded by MCIN/AEI/10.13039/501100011039 and by the “European Union Next Generation EU/PRTR”, the Regional Government of Castile and León (CSI144P20). J.P.L. and P.L.S. are supported by the Carlos III Health Institute (PIE14/00066). AGN laboratory and human patients’ studies are supported by an ISCIII project grant (PI18/01242). The Human Genotyping unit is a member of CeGen, PRB3, and is supported by grant PT17/0019 of the PE I + D + i 2013–2016, funded by ISCIII and ERDF. SCLl is supported by MINECO/FEDER research grants (RTI2018-094130-B-100). CH was supported by the Department of Defense (DoD) BCRP, No. BC190820; and the National Cancer Institute (NCI) at the National Institutes of Health (NIH), No. R01CA184476. Lawrence Berkeley National Laboratory (LBNL) is a multi-program national laboratory operated by the University of California for the DOE under contract DE AC02-05CH11231. The Proteomics Unit belongs to ProteoRed, PRB3-ISCIII, supported by grant PT17/0019/0023 of the PE I + D +i, 2017–2020, funded by ISCIII and FEDER. RCC is funded by fellowships from the Spanish Regional Government of Castile and León. NGS is a recipient of an FPU fellowship (MINECO/FEDER). hiPSC-CM studies were funded in part by the “la Caixa” Banking Foundation under the project code HR18-00304 and a Severo Ochoa CNIC Intramural Project (Exp. 12-2016 IGP) to J.J., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Pan-cancer evaluation of clinical value of mitotic network activity index (MNAI) and its predictive value for immunotherapy

  • Mao, Xuanyu
  • Cai, Yimeng
  • Long, Sarah
  • Pérez-Losada, J.
  • Mao, Jian-Hua
  • Chang, Hang
Increased mitotic activity is associated with the genesis and aggressiveness of many cancers. To assess the clinical value of mitotic activity as prognostic biomarker, we performed a pan-cancer study on the mitotic network activity index (MNAI) constructed based on 54-gene mitotic apparatus network. Our pan-cancer assessment on TCGA (33 tumor types, 10,061 patients) and validation on other publicly available cohorts (23 tumor types, 9,209 patients) confirmed the significant association of MNAI with overall survival, progression-free survival, and other prognostic endpoints in multiple cancer types, including lower-grade gliomas (LGG), breast invasive carcinoma (BRCA), as well as many others. We also showed significant association between MNAI and genetic instability, which provides a biological explanation of its prognostic impact at pan-cancer landscape. Our association analysis revealed that patients with high MNAI benefitted more from anti-PD-1 and Anti-CTLA-4 treatment. In addition, we demonstrated that multimodal integration of MNAI and the AI-empowered Cellular Morphometric Subtypes (CMS) significantly improved the predictive power of prognosis compared to using MNAI and CMS alone. Our results suggest that MNAI can be used as a potential prognostic biomarker for different tumor types toward different clinical endpoints, and multimodal integration of MNAI and CMS exceeds individual biomarker for precision prognosis., This work was supported by the Department of Defense (DoD) BCRP, No. BC190820; and the National Cancer Institute (NCI) at the National Institutes of Health (NIH), No. R01CA184476. Lawrence Berkeley National Laboratory (LBNL) is a multi-program national laboratory operated by the University of California for the DOE under contract DE AC02-05CH11231. Perez-Losada’s lab is sponsored by Grant PID2020-118527RB-I00 funded by MCIN/AEI/10.13039/501100011039; Grant PDC2021-121735-I00 funded by MCIN/AEI/10.13039/501100011039 and by the “European Union Next Generation EU/PRTR”, the Regional Government of Castile and León (CSI144P20)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The Role of GAB1 in Cancer

  • Pérez-Baena, Manuel Jesús
  • Cordero-Pérez, Francisco Josué
  • Pérez-Losada, J.
  • Holgado-Madruga, Marina
GRB2-associated binder 1 (GAB1) is the inaugural member of the GAB/DOS family of pleckstrin homology (PH) domain-containing proteins. Upon receiving various stimuli, GAB1 transitions from the cytoplasm to the membrane where it is phosphorylated by a range of kinases. This event recruits SH2 domain-containing proteins like SHP2, PI3K’s p85 subunit, CRK, and others, thereby activating distinct signaling pathways, including MAPK, PI3K/AKT, and JNK. GAB1-deficient embryos succumb in utero, presenting with developmental abnormalities in the heart, placenta, liver, skin, limb, and diaphragm myocytes. Oncogenic mutations have been identified in the context of cancer. GAB1 expression levels are disrupted in various tumors, and elevated levels in patients often portend a worse prognosis in multiple cancer types. This review focuses on GAB1’s influence on cellular transformation particularly in proliferation, evasion of apoptosis, metastasis, and angiogenesis—each of these processes being a cancer hallmark. GAB1 also modulates the resistance/sensitivity to antitumor therapies, making it a promising target for future anticancer strategies., This work was supported in JPL’s lab by Grant PID2020-118527RB-I00 funded by MCIN/AEI/10.13039/501100011039; Grant PDC2021-121735-I00 funded by MCIN/AEI/10.13039/501100011039 and by the “European Union Next Generation EU/PRTR”, the Regional Government of Castile and León (CSI234P18 and CSI144P20). M.J.P.-B. is a recipient of an FPU fellowship (MINECO/FEDER)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

iCEMIGE: Integration of CEll-morphometrics, MIcrobiome, and GEne biomarker signatures for risk stratification in breast cancers

  • Mao, Xuan-Yu
  • Pérez-Losada, J.
  • Abad, María del Mar
  • Rodríguez-González, Marta
  • Rodríguez-Sánchez, César Augusto
  • Mao, Jian-Hua
  • Chang, Hang
[Aim] To investigate whether iCEMIGE (integration of CEll-morphometrics, MIcro biome, and GEne biomarker signatures) improves risk stratification of breast cancer (BC) patients., [Methods] We used our recently developed machine learning technique to identify cellular morphometric biomarkers (CMBs) from the whole histological slide images in The Cancer Genome Atlas (TCGA) breast cancer (TCGA-BRCA) cohort. Multivariate Cox regression was used to assess whether cell-morphometrics prognosis score (CMPS) and our previously reported 12-gene expression prognosis score (GEPS) and 15-microbe abundance prognosis score (MAPS) were independent prognostic factors. iCEMIGE was built upon the sparse representation learning technique. The iCEMIGE scoring model performance was measured by the area under the receiver operating characteristic curve compared to CMPS, GEPS, or MAPS alone. Nomogram models were created to predict overall survival (OS) and progress-free survival (PFS) rates at 5- and 10-year in the TCGA-BRCA cohort., [Results] We identified 39 CMBs that were used to create a CMPS system in BCs. CMPS, GEPS, and MAPS were found to be significantly independently associated with OS. We then established an iCEMIGE scoring system for risk stratification of BC patients. The iGEMIGE score has a significant prognostic value for OS and PFS independent of clinical factors (age, stage, and estrogen and progesterone receptor status) and PAM50-based molecular subtype. Importantly, the iCEMIGE score significantly increased the power to predict OS and PFS compared to CMPS, GEPS, or MAPS alone., [Conclusion] Our study demonstrates a novel and generic artificial intelligence framework for multimodal data integration toward improving prognosis risk stratification of BC patients, which can be extended to other types of cancer., This work was supported by the Department of Defense (DoD) BCRP, No. BC190820; the National Cancer Institute (NCI) at the National Institutes of Health (NIH), No. R01CA184476; MCIN/AEI/10.13039/501100011039, No. PID2020-118527RB-I00, and No. PDC2021-121735-I00; and the “European Union Next Generation EU/PRTR.” the Regional Government of Castile and León, No. CSI144P20. Lawrence Berkeley National Laboratory (LBNL) is a multi-program national laboratory operated by the University of California for the DOE under contract DE AC02-05CH11231., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A susceptibility gene signature for ERBB2-driven mammary tumour development and metastasis in collaborative cross mice

  • Yang, Hui
  • Wang, Xinzhi
  • Blanco-Gómez, Adrián
  • He, Li
  • García-Sancha, Natalia
  • Corchado Cobos, Roberto
  • Pérez-Baena, Manuel Jesús
  • Jiménez-Navas, Alejandro
  • Wang, Pin
  • Inman, Jamie L.
  • Snijders, Antoine M.
  • Threadgill, David W.
  • Balmain, Allan
  • Chang, Hang
  • Pérez-Losada, J.
  • Mao, Jian-Hua
[Background]: Deeper insights into ERBB2-driven cancers are essential to develop new treatment approaches for ERBB2+ breast cancers (BCs). We employed the Collaborative Cross (CC) mouse model to unearth genetic factors underpinning Erbb2-driven mammary tumour development and metastasis., [Methods]: 732 F1 hybrid female mice between FVB/N MMTV-Erbb2 and 30 CC strains were monitored for mammary tumour phenotypes. GWAS pinpointed SNPs that influence various tumour phenotypes. Multivariate analyses and models were used to construct the polygenic score and to develop a mouse tumour susceptibility gene signature (mTSGS), where the corresponding human ortholog was identified and designated as hTSGS. The importance and clinical value of hTSGS in human BC was evaluated using public datasets, encompassing TCGA, METABRIC, GSE96058, and I-SPY2 cohorts. The predictive power of mTSGS for response to chemotherapy was validated in vivo using genetically diverse MMTV-Erbb2 mice., [Findings]: Distinct variances in tumour onset, multiplicity, and metastatic patterns were observed in F1-hybrid female mice between FVB/N MMTV-Erbb2 and 30 CC strains. Besides lung metastasis, liver and kidney metastases emerged in specific CC strains. GWAS identified specific SNPs significantly associated with tumour onset, multiplicity, lung metastasis, and liver metastasis. Multivariate analyses flagged SNPs in 20 genes (Stx6, Ramp1, Traf3ip1, Nckap5, Pfkfb2, Trmt1l, Rprd1b, Rer1, Sepsecs, Rhobtb1, Tsen15, Abcc3, Arid5b, Tnr, Dock2, Tti1, Fam81a, Oxr1, Plxna2, and Tbc1d31) independently tied to various tumour characteristics, designated as a mTSGS. hTSGS scores (hTSGSS) based on their transcriptional level showed prognostic values, superseding clinical factors and PAM50 subtype across multiple human BC cohorts, and predicted pathological complete response independent of and superior to MammaPrint score in I-SPY2 study. The power of mTSGS score for predicting chemotherapy response was further validated in an in vivo mouse MMTV-Erbb2 model, showing that, like findings in human patients, mouse tumours with low mTSGS scores were most likely to respond to treatment., [Interpretation]: Our investigation has unveiled many new genes predisposing individuals to ERBB2-driven cancer. Translational findings indicate that hTSGS holds promise as a biomarker for refining treatment strategies for patients with BC., The U.S. Department of Defense (DoD) Breast Cancer Research Program (BCRP) (BC190820), United States; MCIN/AEI/10.13039/501100011039 (PID2020-118527RB-I00, PDC2021-121735-I00), the “European Union Next Generation EU/PRTR,” the Regional Government of Castile and León (CSI144P20), European Union., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Understanding Susceptibility to Breast Cancer: From Risk Factors to Prevention Strategies

  • García-Sancha, Natalia
  • Corchado Cobos, Roberto
Breast cancer is the most common malignancy among women globally, with incidence rates continuing to rise. A comprehensive understanding of its risk factors and the underlying biological mechanisms that drive tumor initiation is essential for developing effective prevention strategies. This review examines key non-modifiable risk factors, such as genetic predisposition, demographic characteristics, family history, mammographic density, and reproductive milestones, as well as modifiable risk factors like exogenous hormone exposure, obesity, diet, and physical inactivity. Importantly, reproductive history plays a dual role, providing long-term protection while temporarily increasing breast cancer risk shortly after pregnancy. Current chemoprevention strategies primarily depend on selective estrogen receptor modulators (SERMs), including tamoxifen and raloxifene, which have demonstrated efficacy in reducing the incidence of estrogen receptor-positive breast cancer but remain underutilized due to adverse effects. Emerging approaches such as aromatase inhibitors, RANKL inhibitors, progesterone antagonists, PI3K inhibitors, and immunoprevention strategies show promise for expanding preventive options. Understanding the interactions between risk factors, hormonal influences, and tumorigenesis is critical for optimizing breast cancer prevention and advancing safer, more targeted chemopreventive interventions, This work carried out in JPL’s laboratory, was supported by Grant SAF2017-88854R, funded by MCIN/AEI/10.13039/501100011039 and by “ERDF A way of making Europe”; Grants PID2020-118527RB-I00 and PDC2021-121735-I00, funded by MCIN/AEI/10.13039/501100011039 and by the “European Union Next Generation EU/PRTR”; Grant PID2023-153081OB-I00, funded by MCIN/AEI/10.13039/501100011039; the Regional Government of Castile and León (CSI144P20); and the “We can be heroes” charity. N.G.-S. was a recipient of an FPU fellowship (MECD-FPU17/00192). R.C.-C. was founded by a fellowship from the Spanish Regional Government of Castile and León., Peer reviewed
Docta Complutense
Publicación Artículo científico (JournalArticle)

Evolutionary Origins of Metabolic Reprogramming in Cancer

  • García-Sancha, Natalia
  • Corchado-Cobos, Roberto
  • Gómez-Vecino, Aurora
  • Jiménez-Navas, Alejandro
  • Pérez-Baena, Manuel Jesús
  • Blanco-Gómez, Adrián
  • Holgado-Madruga, Marina
  • Jian-Hua, Mao
  • Cañueto, Javier
  • Castillo Lluva, Sonia
  • Mendiburu-Eliçabe Garganta, Marina
  • Pérez-Losada, Jesús
Metabolic changes that facilitate tumor growth are one of the hallmarks of cancer. These changes are not specific to tumors but also take place during the physiological growth of tissues. Indeed, the cellular and tissue mechanisms present in the tumor have their physiological counterpart in the repair of tissue lesions and wound healing. These molecular mechanisms have been acquired during metazoan evolution, first to eliminate the infection of the tissue injury, then to enter an effective regenerative phase. Cancer itself could be considered a phenomenon of antagonistic pleiotropy of the genes involved in effective tissue repair. Cancer and tissue repair are complex traits that share many intermediate phenotypes at the molecular, cellular, and tissue levels, and all of these are integrated within a Systems Biology structure. Complex traits are influenced by a multitude of common genes, each with a weak effect. This polygenic component of complex traits is mainly unknown and so makes up part of the missing heritability. Here, we try to integrate these different perspectives from the point of view of the metabolic changes observed in cancer.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Intermediate Molecular Phenotypes to Identify Genetic Markers of Anthracycline-Induced Cardiotoxicity Risk

  • Gómez Vecino, Aurora
  • Corchado Cobos, Roberto
  • Blanco Gómez, Adrián
  • García Sancha, Natalia
  • Martín García, Ana
  • Mendiburu-Eliçabe Garganta, Marina
  • Prieto, Carlos
  • Ruiz Pinto, Sara
  • Pita, Guillermo
  • Velasco Ruiz, Alejandro
  • Patino Alonso, Carmen
  • Galindo Villardón, Purificación
  • Linarejos Vera Pedrosa, María
  • Jalife, José
  • Mao, Jian-Hua
  • Macías de Plasencia, Guillermo
  • Castellanos Martín, Andrés
  • Sáez Freire, María del Mar
  • Fraile Martín, Susana
  • Rodrigues Teixeira, Telmo
  • García Macías, Carmen
  • Galvis Jiménez, Julie Milena
  • Castillo Lluva, Sonia
  • García Sánchez, Asunción
  • Isidoro García, María
  • Fuentes, Manuel
  • García Cenador, María Begoña
  • García Criado, Francisco Javier
  • García Hernández, Juan Luis
  • Hernández García, María Ángeles
  • Cruz Hernández, Juan Jesús
  • Rodríguez Sánchez, César Augusto
  • Martín García-Sancho, Alejandro
  • Pérez López, Estefanía
  • Pérez Martínez, Antonio
  • Gutiérrez-Larraya Aguado, Federico
  • Cartón, Antonio J.
  • García Sáenz, José Ángel
  • Patiño-García, Ana
  • Martín, Miguel
  • Alonso Gordoa, Teresa
  • Vulsteke, Christof
  • Croes, Lieselot
  • Hatse, Sigrid
  • Van Brussel, Thomas
  • Lambrechts, Diether
  • Wildiers, Hans
  • Hang, Chang
  • Holgado Madruga, Marina
  • González-Neira, Anna
  • Sánchez, Pedro L.
  • Pérez Losada, Jesús
Cardiotoxicity due to anthracyclines (CDA) affects cancer patients, but we cannot predict who may suffer from this complication. CDA is a complex trait with a polygenic component that is mainly unidentified. We propose that levels of intermediate molecular phenotypes (IMPs) in the myocardium associated with histopathological damage could explain CDA susceptibility, so variants of genes encoding these IMPs could identify patients susceptible to this complication. Thus, a genetically heterogeneous cohort of mice (n = 165) generated by backcrossing were treated with doxorubicin and docetaxel. We quantified heart fibrosis using an Ariol slide scanner and intramyocardial levels of IMPs using multiplex bead arrays and QPCR. We identified quantitative trait loci linked to IMPs (ipQTLs) and cdaQTLs via linkage analysis. In three cancer patient cohorts, CDA was quantified using echocardiography or Cardiac Magnetic Resonance. CDA behaves as a complex trait in the mouse cohort. IMP levels in the myocardium were associated with CDA. ipQTLs integrated into genetic models with cdaQTLs account for more CDA phenotypic variation than that explained by cda-QTLs alone. Allelic forms of genes encoding IMPs associated with CDA in mice, including AKT1, MAPK14, MAPK8, STAT3, CAS3, and TP53, are genetic determinants of CDA in patients. Two genetic risk scores for pediatric patients (n = 71) and women with breast cancer (n = 420) were generated using machine-learning Least Absolute Shrinkage and Selection Operator (LASSO) regression. Thus, IMPs associated with heart damage identify genetic markers of CDA risk, thereby allowing more personalized patient management.